NASH Market Outlook 2037

1.1. Study Objective
1.2. Scope of the report
1.3. Market Taxonomy

2.1. Research Methodology
2.2. Secondary Research
2.3. Primary Research
2.4. SPSS Approach
2.5. Data Triangulation

4.1. Market Overview
4.2. Regional Synopsis
4.3. Industry Supply Chain Analysis
4.4. DROT
4.4.1. Driver
4.4.2. Restraint
4.4.3. Opportunities
4.4.4. Trends
4.5. Government Regulation: How they would Aid the Business?
4.6. Competitive Landscape
4.6.1. AstraZeneca PLC
4.6.2. Eli Lilly & Company
4.6.3. Galmed Pharmaceuticals Ltd.
4.6.4. GENFIT S.A.
4.6.5. Novo Nordisk A/S
4.6.6. Novartis AG
4.6.7. PFIZER INC.
4.6.8. Siemens Healthineers AG
4.6.9. TAKEDA PHARMACEUTICAL COMPANY LIMITED
4.6.10. Zydus Lifesciences Limited
4.7. SWOT Analysis
4.8. Comparative Analysis Of The Current Technologies
4.9. Company Share in The Market
4.10. Analysis of Strategic Initiatives Adopted by Key Players
4.11. Drug Type Analysis
4.12. Growth Forecast of Non-Alcoholic Steatohepatitis (NASH) Drugs and Diagnostics Market
4.13. Patent Analysis
4.14. Recent Developments
4.15. Industry Risk Assessment

5.1. Global Overview
5.1.1. Market Value (USD Million), Current and Future Projections, 2024-2037
5.1.2. Increment $ Opportunity Assessment, 2024-2037
5.1.3. Year-on-Year Growth Forecast (%)
5.2. Global Segmentation (USD Million), 2024-2037, By
5.2.1. Drug Type, Value (USD Million)
5.2.1.1. Vitamin E and Pioglitazone
5.2.1.2. Obeticholic Acid (OCA)
5.2.1.3. Lanifibranor
5.2.1.4. Semaglutide
5.2.1.5. Resmetirom
5.2.1.6. Aramchol
5.2.1.7. Cenicriviroc
5.2.1.8. Others
5.2.2. End user, Value (USD Million)
5.2.2.1. Hospital Pharmacies
5.2.2.2. Retail and Specialty Pharmacies
5.2.2.3. Others
5.3. Regional Synopsis (USD Million), 2024-2037
5.3.1.1. North America, Value (USD Million)
5.3.1.2. Europe, Value (USD Million)
5.3.1.3. Asia Pacific, Value (USD Million)
5.3.1.4. Latin America, Value (USD Million)
5.3.1.5. Middle East and Africa, Value (USD Million)
5.4. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037

6.1. Overview
6.1.1. Market Value (USD Million), Current and Future Projections, 2024-2037
6.1.2. Increment $ Opportunity Assessment, 2024-2037
6.2. Segmentation (USD Million), 2024-2037, By
6.2.1. Drug Type, Value (USD Million)
6.2.1.1. Vitamin E and Pioglitazone
6.2.1.2. Obeticholic Acid (OCA)
6.2.1.3. Lanifibranor
6.2.1.4. Semaglutide
6.2.1.5. Resmetirom
6.2.1.6. Aramchol
6.2.1.7. Cenicriviroc
6.2.1.8. Others
6.2.2. End user, Value (USD Million)
6.2.2.1. Hospital Pharmacies
6.2.2.2. Retail and Specialty Pharmacies
6.2.2.3. Others
6.2.3. Country Level Analysis, Value (USD Million)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037

7.1. Overview
7.1.1. Market Value (USD Million), Current and Future Projections, 2024-2037
7.1.2. Increment $ Opportunity Assessment, 2024-2037
7.2. Segmentation (USD Million), 2024-2037, By
7.2.1. Drug Type, Value (USD Million)
7.2.1.1. Vitamin E and Pioglitazone
7.2.1.2. Obeticholic Acid (OCA)
7.2.1.3. Lanifibranor
7.2.1.4. Semaglutide
7.2.1.5. Resmetirom
7.2.1.6. Aramchol
7.2.1.7. Cenicriviroc
7.2.1.8. Others
7.2.2. End user, Value (USD Million)
7.2.2.1. Hospital Pharmacies
7.2.2.2. Retail and Specialty Pharmacies
7.2.2.3. Others
7.2.3. Country Level Analysis, Value (USD Million)
7.2.3.1. UK
7.2.3.2. Germany
7.2.3.3. France
7.2.3.4. Italy
7.2.3.5. Spain
7.2.3.6. NORDIC
7.2.3.7. Russia
7.2.3.8. Rest of Europe
7.3. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037

8.1. Overview
8.1.1. Market Value (USD Million), Current and Future Projections, 2024-2037
8.1.2. Increment $ Opportunity Assessment, 2024-2037
8.2. Segmentation (USD Million), 2024-2037, By
8.2.1. Drug Type, Value (USD Million)
8.2.1.1. Vitamin E and Pioglitazone
8.2.1.2. Obeticholic Acid (OCA)
8.2.1.3. Lanifibranor
8.2.1.4. Semaglutide
8.2.1.5. Resmetirom
8.2.1.6. Aramchol
8.2.1.7. Cenicriviroc
8.2.1.8. Others
8.2.2. End user, Value (USD Million)
8.2.2.1. Hospital Pharmacies
8.2.2.2. Retail and Specialty Pharmacies
8.2.2.3. Others
8.2.3. Country Level Analysis, Value (USD Million)
8.2.3.1. China
8.2.3.2. Japan
8.2.3.3. India
8.2.3.4. Australia
8.2.3.5. South Korea
8.2.3.6. Vietnam
8.2.3.7. Thailand
8.2.3.8. Singapore
8.2.3.9. Malaysia
8.2.3.10. Rest of Asia Pacific
8.3. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037

9.1. Overview
9.1.1. Market Value (USD Million), Current and Future Projections, 2024-2037
9.1.2. Increment $ Opportunity Assessment, 2024-2037
9.2. Segmentation (USD Million), 2024-2037, By
9.2.1. Drug Type, Value (USD Million)
9.2.1.1. Vitamin E and Pioglitazone
9.2.1.2. Obeticholic Acid (OCA)
9.2.1.3. Lanifibranor
9.2.1.4. Semaglutide
9.2.1.5. Resmetirom
9.2.1.6. Aramchol
9.2.1.7. Cenicriviroc
9.2.1.8. Others
9.2.2. End user, Value (USD Million)
9.2.2.1. Hospital Pharmacies
9.2.2.2. Retail and Specialty Pharmacies
9.2.2.3. Others
9.2.3. Country Level Analysis, Value (USD Million)
9.2.3.1. Brazil
9.2.3.2. Mexico
9.2.3.3. Argentina
9.2.3.4. Rest of Latin America
9.3. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037

10.1. Overview
10.1.1. Market Value (USD Million), Current and Future Projections, 2024-2037
10.1.2. Increment $ Opportunity Assessment, 2024-2037
10.2. Segmentation (USD Million), 2024-2037, By
10.2.1. Drug Type, Value (USD Million)
10.2.1.1. Vitamin E and Pioglitazone
10.2.1.2. Obeticholic Acid (OCA)
10.2.1.3. Lanifibranor
10.2.1.4. Semaglutide
10.2.1.5. Resmetirom
10.2.1.6. Aramchol
10.2.1.7. Cenicriviroc
10.2.1.8. Others
10.2.2. End user, Value (USD Million)
10.2.2.1. Hospital Pharmacies
10.2.2.2. Retail and Specialty Pharmacies
10.2.2.3. Others
10.2.3. Country Level Analysis, Value (USD Million)
10.2.3.1. GCC
10.2.3.2. Israel
10.2.3.3. South Africa
10.2.3.4. Rest of Middle East & Africa
10.3. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037

11.1. World Economic Outlook

12.1. Global Clientele
12.2. We Serve Clients Across World